ClinicalTrials.gg
RecruitingNCT06967207Updated May 13, 2025

Electrical Impedance Tomography-Based Prognostic Model for ARDS

An observational study in Acute Respiratory Distress Syndrome (ARDS) and Ventilator-induced Lung Injury, sponsored by XiaoJing Zou,MD. Recruiting at 4 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-05-13.

Sponsored by XiaoJing Zou,MD · Observational

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
625
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 146 studies in Respiratory Distress Syndrome with a site in China — 54 open to participants now, 55 under way, 6 of them phase 3. Respiratory Distress Syndrome · China.

Planned enrollment
14th of 65
625 · median 139
Started
2025
with 12 others
Observational
65 of 146
22 open now
Primary completion
2027-12
later than 43 of 54 live
Registered
118th of 146
by date

Among the 146 studies in Respiratory Distress Syndrome with a site in China, this one is the 14th largest by planned enrollment of the 65 observational ones that give a count, is one of 13 that started in 2025, is one of 65 observational ones, reaches primary completion later than 43 of the 54 other live ones, and was the 118th registered.

Respiratory Distress Syndrome

1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Open to participants now

54 of the 146 studies in Respiratory Distress Syndrome with a site in China are open now. Recruiting first, the newest first:

48 more — sign in →

All 54 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 146 studies in Respiratory Distress Syndrome with a site in China, or all of them as a file.
02

Study summary

This multicenter, prospective, observational study aims to develop and validate an EIT-based prognostic model for ARDS. By focusing on the pathophysiological characteristics of ARDS and the causes of ventilator-induced lung injury, the investigators intend to establish a prognostic model that reveals lung injury and heterogeneity, enabling risk stratification and guiding individualized treatment.

03

Conditions studied

  • Acute Respiratory Distress Syndrome (ARDS)
  • Ventilator-induced Lung Injury
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This is a prospective, multicenter, observational cohort study that will enroll adult patients (aged 18-80 years) diagnosed with acute respiratory distress syndrome (ARDS) per the new 2023 ARDS global definition.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Meet the new 2023 ARDS global definition;
  2. Age 18-80 years

Exclusion criteria

Exclusion Criteria:

  1. Expected death within 24 hours of screening;
  2. cancer (active with distant metastases);
  3. Severe psychiatric disorders;
  4. Pregnancy or postpartum status;
  5. Pneumothorax or moderate to large pleural effusion without adequate drainage;
  6. Chronic respiratory failure;
  7. Patients with pulmonary embolism or pulmonary hypertension;
  8. Heart failure patients: EF \<50% or class III or IV;
  9. Patient/family refusal to participate;
  10. Participation in another interventional trial within 3 months prior to enrollment
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
625 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • ARDS Patients for Training cohort

    Training cohort

    Other: Not applicable- observational study

  • ARDS Patients for Validation cohort

    Validation cohort

    Other: Not applicable- observational study

Interventions

  • OtherNot applicable- observational study

    Not applicable- observational study

06

What researchers measure

Primary outcomes

  1. 28-day mortality rate

    Time frame: From date of study enrollment (Day 0) until Day 28

Secondary outcomes

  1. ICU mortality rate

    Time frame: From ICU admission to discharge, up to 24 weeks

  2. 60-day all-cause mortality rate

    Time frame: 60 days post-enrollment

  3. 90-day all-cause mortality rate

    Time frame: 90 days post-enrollment

  4. Duration of mechanical ventilation (days)

    Time frame: From intubation to successful extubation, up to 28 days

  5. Ventilator-free days (VFDs) at 28 days

    Time frame: 28 days post-enrollment

  6. ICU length of stay (days)

    Time frame: From ICU admission to discharge, up to 24 weeks

  7. Hospital length of stay

    Time frame: From hospital admission to discharge, up to 24 weeks

07

Study locations

4 of 4 sites recruiting
  • Department of Critical Care Medicine, Guangdong Provincial People's Hospital
    Guangzhou, Guangdong, China
    Recruiting
  • Department of Critical Care Medicine, Renmin Hospital of Wuhan University
    Wuhan, Hubei, China
    Recruiting
  • Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China Department of
    Wuhan, Hubei, China
    Recruiting
  • Department of Emergency, Zhongshan Hospital, Fudan University
    Shanghai, Shanghai, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Dec 2027, 32 months after the start.

Of 228 non-industry observational studies under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 32 months is above that.

Counting every sponsor, half of 234 studies reached it within 24 months; a quarter within 12 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2025
First posted
May 13, 2025
StartActual
Apr 15, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
May 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06967207
Lead sponsor
XiaoJing Zou,MD
Responsible party
XiaoJing Zou,MD (MD, Wuhan Union Hospital, China) — Sponsor-investigator
First posted
May 13, 2025
Start date
Apr 15, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
May 13, 2025

Study contacts

Xiaojing Zou Zou
Contact
249126734@qq.com
84+13995518630
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion